Results 21 to 30 of about 85,963 (263)

Network pharmacology of JAK inhibitors [PDF]

Proceedings of the National Academy of Sciences, 2016
Significance JAK kinase inhibitors (JAKis) have advanced options for treatment of autoimmune diseases. Because JAKs are signaling hubs for several cytokine receptors, JAKis’ overall impact on the immune system and how they actually improve diseases like rheumatoid arthritis remain poorly understood.
Devapregasan, Moodley, Hideyuki, Yoshida, Sara, Mostafavi, Natasha, Asinovski, Adriana, Ortiz-Lopez, Peter, Symanowicz, Jean-Baptiste, Telliez, Martin, Hegen, James D, Clark, Diane, Mathis, Christophe, Benoist   +10 more
openaire   +2 more sources

Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy [PDF]

Journal of Immunotherapy and Precision Oncology, 2021
Myeloproliferative neoplasms (MPNs) are clonal hematopoietic disorders that consist classically of polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF).
Sophia S. Lee, Srdan Verstovsek, Naveen Pemmaraju   +2 more
doaj   +1 more source

1H NMR Study on Serum Metabonomic Alterations Induced by JAK/STAT Pathway Inhibitor in C57BL/6 Mice

Chinese Journal of Magnetic Resonance, 2018
JAK/STAT pathway inhibitor has been used in clinic trial for several diseases. However, the adverse effect of systematic administration of JAK/STAT pathway inhibitors on cellular function is largely unknown.
ZHAO Xin, XIAO Xiong-jie, GAO Dong-li, ZHANG Xian-rong   +3 more
doaj   +1 more source

JAK Inhibitors in Psoriatic Disease

Clinical, Cosmetic and Investigational Dermatology, 2023
Psoriasis is now considered to be the cutaneous phenotype of a systemic inflammatory condition, recognized under the term Psoriatic Disease (PsD). PsD has several extracutaneous manifestations, such as inflammatory articular and entheseal involvement, leading to psoriatic arthritis (PsA), and the less frequent intestinal and ocular manifestations with ...
Megna, Matteo, Potestio, Luca, Ruggiero, Angelo, Cacciapuoti, Sara, Maione, Francesco, Tasso, Marco, Caso, Francesco, Costa, Luisa   +7 more
openaire   +5 more sources

Janus kinase inhibitor use and incident dry eye disease in rheumatoid arthritis: a real-world cohort study

Frontiers in Immunology
PurposeTo examine the association between systemic Janus kinase (JAK) inhibitor use and the incidence of newly diagnosed dry eye disease (DED) in patients with rheumatoid arthritis (RA).MethodsThis multi-institutional retrospective cohort study used de ...
Ching-Chieh Lin, Ching-Chieh Lin, Yang-Chi Lin, Yang-Chi Lin, Renin Chang, Renin Chang, Renin Chang, Chun-Yu Lin, Chun-Yu Lin, Chun-Yu Lin, Jiunn-Liang Chen, Jiunn-Liang Chen   +11 more
doaj   +1 more source

A novel JAK/ROCK inhibitor, CPL409116, demonstrates potent efficacy in the mouse model of systemic lupus erythematosus

Journal of Pharmacological Sciences, 2021
Systemic lupus erythematosus is a chronic inflammatory disease, in which treatment is still limited due to suboptimal efficacy and toxicities associated with the available therapies.
Maria Dulak-Lis, Anna Bujak, Kamila Gala, Martyna Banach, Urszula Kędzierska, Joanna Miszkiel, Joanna Hucz-Kalitowska, Michał Mroczkiewicz, Bartosz Stypik, Krzysztof Szymczak, Paweł Gunerka, Krzysztof Dubiel, Beata M. Zygmunt, Maciej Wieczorek, Jerzy S. Pieczykolan   +14 more
doaj   +1 more source

Efficacy and safety of Ruxolitinib-based combination therapy in the patients with Myelofibrosis (MF): a systematic review and meta-analysis

Annals of Medicine
Background Myelofibrosis (MF) is a chronic myeloproliferative neoplasm. Although Ruxolitinib, a JAK1/2 inhibitor, remains the cornerstone of MF treatment, it does not reverse disease progression, and resistance frequently emerges.
Shuai Tan, Yuxin Li, Yaofang Cao, Wanling Sun, Wuhan Hui   +4 more
doaj   +1 more source

JAK inhibitors and COVID-19

Journal for ImmunoTherapy of Cancer, 2022
During SARS-CoV-2 infection, the innate immune response can be inhibited or delayed, and the subsequent persistent viral replication can induce emergency signals that may culminate in a cytokine storm contributing to the severe evolution of COVID-19. Cytokines are key regulators of the immune response and virus clearance, and, as such, are linked to ...
Levy, G, Guglielmelli, P, Langmuir, P, Constantinescu, S   +3 more
openaire   +4 more sources

European Standard Clinical Practice Guideline and EXPeRT Recommendations for the Diagnosis and Management of Gastroenteropancreatic Neuroendocrine Neoplasms in Children and Adolescents

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Pediatric gastroenteropancreatic neuroendocrine neoplasms (GEP‐NENs) are extremely rare and clinically heterogeneous. Management has largely been extrapolated from adult practice. This European Standard Clinical Practice Guideline (ESCP), developed by the EXPeRT network in collaboration with adult NEN experts, provides (adult) evidence ...
Michaela Kuhlen, Calogero Virgone, Antje Redlich, Michael Abele, Ricardo Lopez‐Almaraz, Tal Ben‐Ami, Ewa Bien, Gianni Bisogno, Maja Mazic Cesen, Andrea Ferrari, Malgorzata A. Krawczyk, Yves Reguerre, Dominik T. Schneider, Ines B. Brecht, Charlotte Rigaud, Bilgehan Yalcin, Rainer Claus, Christian Vokuhl, Constantin Lapa, Jörg Fuchs, Segolene Hescot, Thomas Walter, Julien Hadoux, Daniel Orbach   +23 more
wiley   +1 more source

EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS IN REAL CLINICAL PRACTICE

Научно-практическая ревматология, 2020
Objective: to evaluate the clinical efficacy and safety of the targeted synthetic disease-modifying anti-rheumatic drug (DMARD) tofacitinib (TOFA; Yakvinus®) in patients with active psoriatic arthritis (PsA) at 12 and 24 weeks after starting treatment ...
E. Yu. Loginova, Yu. L. Korsakova, E. E. Gubar, P. L. Karpova, T. V. Korotaeva   +4 more
doaj   +1 more source